Aeterna Zentaris

Entity > Corporation > US > New York City New York > Aeterna Zentaris

About Aeterna Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company engaged in the development and commercialization of therapeutics and diagnostic tests.

Aeterna Zentaris’ Markets Macimorelin: The company markets macimorelin under the brand name Macrilen. Macimorelin is an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates growth hormone secretion by binding to the GHSR-1a for the diagnosis of growth hormone deficiency in adults and in children, as well as for oncology indications. Macrilen™ is currently marketed in the United States under a licensing agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside the United States and Canada.

The Company Has Licensing Agreement With Research Institutes:

Aeterna Zentaris Inc. has a license agreement with the College of Wuerzburg, Germany, to research, develop, manufacture and commercialize a potential COVID -19 vaccine; to develop, manufacture and commercialize a treatment for neuromyelitis optica spectrum disorder; to develop 3D human intestinal tissue models to study infection biology; and for preclinical development for the potential treatment of Parkinson's disease. In addition, the Company has a license agreement with Consilient Health Ltd, Novo Nordisk Novo Nordisk Health Care AG and NK MEDITECH Ltd for the development and commercialization of macimorelin in the United States and Canada, and with the College of Sheffield, United Kingdom, for the research, development, manufacture and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism.

Aeterna’s Mission Is Focused on Leveraging its Research and Clinical Development: The company is focused on leveraging its research and clinical development expertise to develop medicines that improve the lives of patients with high unmet medical needs across a range of therapeutic areas.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about Aeterna Zentaris

Company Attribute Value
Name Aeterna Zentaris
Url zentaris
Google google
Wikidata wikidata

Aeterna Zentaris


New York City, US
28 Jan 2024

New York City, US
28 Jan 2024

Aeterna Zentaris

Page: 1 Desktop | Laptop Devices › quote › AEZS
Aeterna Zentaris Inc. (AEZS) Stock Price, News, Quote & ...
AEterna Zentaris Inc. (@AEZS_inc) · X › quotes › AEZS
AEZS: Aeterna Zentaris Inc - Stock Price, Quote and News
AEterna Zentaris Inc. › ... › Stocks › Canada
AEterna Zentaris Inc. Stock Quote (Canada - AEZS › Home › Medicines
GHRYVELIN (previously Macimorelin Aeterna Zentaris)
Related Searches
Related Searches
Aeterna zentaris stock prediction
Aeterna zentaris stock forecast
aeterna zentaris careers
Knowledge Panel
Knowledge Panel

Æterna Zentaris (Company)

Aeterna Zentaris is a specialty biotech company commercializing and developing therapeutic and diagnostic tests, particularly for growth hormone deficiency.,particularly%20for%20growth%20hormone%20deficiency.
  • Stock price : AEZS (NASDAQ) $1.86 -0.01 (-0.48%)Jan 26, 4:00 PM EST - Disclaimer
  • Subsidiary : Æterna Zentaris GmbH
  • Headquarters : Charleston, SC
  • Founded : 1990

All information on this page is taken from publicly available sources, and the analysis we provide is a representation of Google's search results for the entity and does not represent any opinion or judgement about the entity by Kalicube itself. If you disagree with this analysis, please contact us and cite this reference : 193768